Effect of photoperiod and estrogen on expression of arginine vasotocin and its oxytocic-like receptor in the shell gland of the Japanese quail.
The avian neurohypophysial hormone arginine vasotocin (AVT) is an important regulatory hormone involved in many physiological processes including fluid balance, blood pressure regulation, stress responses and reproductive events including oviposition. The mechanisms by which AVT stimulates myometrial contraction during oviposition are not well established in birds. In the present study, immunohistochemistry and in situ hybridization were used to localize AVT and the oxytocin-like VT3 receptor in the shell gland of Japanese quail (Coturnix coturnix japonica). Using an AVT-specific antibody, immunoreactive AVT (ir-AVT) was observed in the myometrium of both photosensitive and photorefractory birds. Similarly, VT3 receptor gene transcripts were detected in the myometrial layer of the shell gland of both photosensitive and photorefractory birds. Body mass, shell gland mass and length of mucosal folds of the shell gland of photosensitive birds was higher compared to that of photorefractory birds. Treatment of photorefractory birds with estrogen increased shell gland activity (mass and length of mucosal folds) and levels of both AVT and VT3 receptor mRNA, whereas treatment of photosensitive birds with the estrogen antagonist tamoxifen decreased shell gland activity and levels of both AVT and VT3 receptor mRNA. Our results suggest that shell gland contractility in response to AVT may be regulated during the reproductive cycle of the Japanese quail and that, in part, this regulation is estrogen-dependent.
Srivastava
Rashmi
R
Department of Zoology, Banaras Hindu University, Varanasi, 221005, India.
Cornett
Lawrence E
LE
Chaturvedi
Chandra Mohini
CM
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D003370:Coturnix / Q000378:metabolism*; D004717:Endometrium / Q000187:drug effects / Q000378:metabolism; D004958:Estradiol / Q000031:analogs & derivatives* / Q000494:pharmacology; D004965:Estrogen Antagonists / Q000494:pharmacology; D005260:Female; D009215:Myometrium / Q000187:drug effects / Q000378:metabolism; D009929:Organ Size / Q000187:drug effects; D010058:Oviposition / Q000187:drug effects*; D017440:Photoperiod; D012333:RNA, Messenger / Q000378:metabolism; D017483:Receptors, Vasopressin / Q000235:genetics / Q000378:metabolism*; D013629:Tamoxifen / Q000494:pharmacology; D013997:Time Factors; D014590:Uterine Contraction / Q000187:drug effects*; D014599:Uterus / Q000187:drug effects* / Q000254:growth & development / Q000378:metabolism; D014668:Vasotocin / Q000235:genetics / Q000378:metabolism*
D004965:Estrogen Antagonists; D012333:RNA, Messenger; D017483:Receptors, Vasopressin; C034862:vasotocin receptor; D013629:Tamoxifen; C074283:estradiol 3-benzoate; D004958:Estradiol; D014668:Vasotocin